Allogene Therapeutics, Inc., has announced the pricing of an underwritten public offering of 11,702,128 shares of its common stock at a price to the public of US$47.00 per share. The gross proceeds from this offering are expected to be approximately US$550.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Allogene. The offering is expected to close on or about June 4, 2020, subject to customary closing conditions. In addition, Allogene has granted the underwriters a 30-day option to purchase up to 1,755,319 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.
Latham & Watkins LLP represents the underwriters in the transaction with a capital markets team led by Bay Area partner Brian Cuneo and Orange County partner Shayne Kennedy, with Bay Area associates Phillip Stoup, Tess Bloom, and Taimi Jacobson. Advice was also provided on regulatory matters by Washington, D.C. partner Elizabeth Richards, with Bay Area counsel Betty Pang and Washington, D.C. associate Chad Jennings; on intellectual property matters by Bay Area partner Judith Hasko, with associate Gavin Liu; and on tax matters by Bay Area partner Grace Lee, with associate Jessica Chen.